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INTRODUCTION
Intravenous immune globulin (IVIG) is a complex prod-
uct, derived from plasma, that has been used as an adjunct to
antibacterial and antiviral therapy, in addition to other
effects, especially in immunodeficient patients [1-3].
Although this agent has been used extensively and, in gen-
eral, is well-tolerated and safe, disadvantages include its high
cost and the requirement for parenteral administration. In
addition to therapy for primary immunodeficiency, IVIG
has been used in Kawasaki’s disease, idiopathic thrombocy-
topenic purpura, Guillain-Barré syndrome, polyradiculopa-
thy, multiple sclerosis, myasthenia gravis, dermatomyositis,
polymyositis, solid organ transplant antirejection therapy,
systemic lupus erythematosus, and allergic disorders [4-10].
Rigorous scientiﬁc data supporting the use of IVIG in many
disorders, however, may be lacking. The Food and Drug
Administration (FDA) has approved the use of IVIG in
6 different conditions: primary immunodeficiencies,
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ABSTRACT
Intravenous immune globulin (IVIG) therapy has been prescribed in many different disease states. Hyperimmune
products are also available. Recently, routine use for many indications has come under scrutiny secondary to high
cost, limited supply, and unclear benefit. IVIG is U.S. Food and Drug Administration–approved for application in
hematopoietic stem cell transplantation (HSCT), a very common indication for its use. In an attempt to clarify the
most appropriate indications and doses in HSCT recipients, we conducted a MEDLINE search in which we reviewed
all relevant articles from 1966 to the present. Search terms included bone marrow transplantation, intravenous
immune globulin, hyperimmune globulin, GVHD, and cytomegalovirus (CMV). Also, the references of all pertinent
studies and review articles were scanned for studies missed via MEDLINE. CMV prophylaxis/treatment and GVHD
prophylaxis are the 2 indications with the most significant clinical support, but there are very few prospective, ran-
domized, controlled trials reported. Furthermore, sample size usually was small, included heterogeneous patient
populations, and employed different primary end points. Several reports support IVIG therapy in combination with
ganciclovir for prevention and treatment of CMV infection, whereas others have shown ganciclovir monotherapy to
be effective, blurring the benefit of IVIG administration. CMV IgG data are also imprecise and difficult to interpret.
The role of IVIG therapy in prevention and treatment of GVHD also is vague. Only 1 randomized investigation
showed a benefit in the prevention of acute GVHD, and no studies showed efficacy in chronic GVHD prophylaxis
and therapy. 
Reports examining the utility of IVIG or CMV IgG in HSCT are hampered by marked variation in trial design
and dosing and diverse patient characteristics. Although IVIG may be useful as a component of preemptive therapy
and treatment of CMV disease, its contribution to the prevention of reactivation of CMV infection is dubious.
Extended IVIG therapy during GVHD prevention may impair recovery of humoral immunity, and its role in pro-
phylaxis and therapy of GVHD has not been clearly defined. Hospital monitoring programs may be a valuable way
to detect areas of high use and allow for streamlining of prescribing.
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immune-mediated thrombocytopenia, Kawasaki’s disease,
hematopoietic stem cell transplantation (HSCT) in patients
at least 20 years of age (Gamimune N only), chronic B-cell
lymphocytic leukemia, and pediatric human immunodefi-
ciency virus type 1 (HIV-1) infection [11]. Recently, the
routine use of IVIG has come under additional scrutiny
because of manufacturer supply problems and escalating
costs [12,13]. An estimated cost for acquisition of IVIG for a
70-kg adult allograft patient prescribed IVIG 250 mg/kg
weekly for 3 months could range anywhere from $8200 to
$12,000 or more. This article will review the data for use of
IVIG in blood and marrow HSCT, one of the common
indications for IVIG therapy. We also describe a program
for monitoring appropriate usage.
IVIG PRODUCTS
Currently, 6 U.S. manufacturers produce IVIG [14].
Hyperimmune immune globulin products are also available.
The latter products may have very high antibody titers to
specific infectious organisms compared to conventional
IVIG. Cytomegalovirus (CMV) immune globulin
(CytoGam) is the product that has been studied in HSCT
patients and will be the only hyperimmune product dis-
cussed herein. The antibody titers against CMV in
CytoGam may be 5 to 8 times higher than in standard IVIG
preparations. All globulin products are manufactured from
plasma pooled from at least 1000 donors and are prepared
via the Cohn-Oncley process or derivative methods, all of
which use cold ethanol to fractionate plasma into immune
globulin fractions [15]. Products are stabilized using glu-
cose, maltose, glycine, sucrose, sorbitol, or albumin [11],
which prevent regeneration of aggregates and anticomple-
mentary activity during storage [15].
IgA DEFICIENCY
IgA deﬁciency is considered a contraindication for use
of IVIG [14,15] because patients may develop IgE antibod-
ies to IgA. Such subjects are at increased risk of anaphylaxis
if exposed to a product containing signiﬁcant quantities of
IgA. However, because most patients are not totally defi-
cient in IgA, this problem is rarely of clinical signiﬁcance.
Patients with known IgA deficiency who require IVIG
preparations should receive a product with the lowest IgA
content available (Gammagard or Polygam) [14-16].
PRODUCT SAFETY AND TOXIC REACTIONS
Although viral contamination is a serious concern with all
blood products, the theoretical risk for spread of blood-
borne pathogens through IVIG use is increased greatly by
virtue of pooling many donor units during production. HIV
and infectious hepatitis are the 2 most serious potential
pathogens. There have been more than 3700 reported cases
of hepatitis C transmission with IVIG administration [15-19].
The vast majority of these cases occurred when plasma units
that tested positive for hepatitis C antibodies were excluded
from use, but before the virus itself could be detected by
polymerase chain reaction (PCR). In recent years, the risk of
transmission of hepatitis C and other enveloped viruses has
been markedly reduced by the use of “solvent/detergent”
and/or other speciﬁc viral inactivation steps. Sporadic reports
of hepatitis B transmission have been published with use of
intramuscular immune globulin and were attributed to use of
contaminated source plasma, poor fractionation methods, or
both. More often, hepatitis B transmission involved the use of
contaminated (nondisposable) needles and syringes for
administering uncontaminated intramuscular products. HIV
has not been transmitted to the authors’ knowledge [18].
Current fractionation and viral inactivation methods used
throughout the manufacturing process are highly effective at
inactivating and removing HIV and other enveloped viruses
from the ﬁnal product [15-18].
Adverse effects associated with IVIG infusion can be
divided into 3 types [16,20]. These untoward events include
immediate adverse effects (occurring during the infusion, eg,
anaphylactoid reactions), delayed adverse effects (occurring
hours to days after initiation of the infusion, eg, renal, pul-
monary, or dermatological adverse effects, hyperviscosity,
aseptic meningitis, arthritis, cerebral infarction, hemolysis,
and leukopenia), and late adverse effects (eg, transmission of
infectious agents). Acute toxic reactions to IVIG also include
fever, chills, nausea, vomiting, malaise, headache, and low
back pain, which typically are infusion rate–related and tran-
sient. The incidence of adverse effects is reported to be
between 1% and 15%, and usually fewer than 5% of patients
experience clinically signiﬁcant reactions in routine practice
[11,15,16]. A less common but potentially irreversible
adverse event is acute renal failure [11,16,21,22]. From June
1985 until November 1998, the FDA received 120 reports
worldwide, 88 in the United States, of renal injury [11]. In
90% of reports, the affected patients received an IVIG prod-
uct that contained sucrose as a stabilizing agent. The postu-
lated mechanism of renal damage was extensive vacuolization
of the proximal tubule secondary to sucrose exposure and
consistent with osmotic injury. From 1985 to 1998, approxi-
mately 40% of the affected patients required hemodialysis,
and in another 15% the renal damage may have contributed
to death [11]. Sucrose-containing products (Sandoglobulin,
Gammar-P IV, Panglobulin, CytoGam) should be avoided in
patients with known renal insufﬁciency.
PHARMACOKINETICS OF IVIG IN HSCT RECIPIENTS
The pharmacokinetics of IVIG in normal subjects and
patients are well known and established [23,24]. The half-
life in normal subjects is approximately 22 days, but in
HSCT patients, the half-life has been shown to be much
shorter, at 6 days [24,25]. It is theorized that the reduced
half-life could be secondary to increased protein catabolism,
acute graft-versus-host disease (GVHD), or both. The vol-
ume of distribution of IVIG in these patients is estimated to
be 0.1 to 0.3 L/kg, indicating very little extravascular distri-
bution and giving support to calculating doses based on
ideal body weight. Based on these data, IVIG is adminis-
tered once weekly in HSCT patients.
THERAPY FOR CMV INFECTION AND DISEASE
CMV is one of the leading causes of infectious morbidity
and mortality in the HSCT population. CMV infection is
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deﬁned as the isolation of CMV from any body site or the
seroconversion of a patient in the absence of any clinical
signs or symptoms of disease. CMV disease is deﬁned as symp-
tomatic infection or a positive culture from deep tissue or his-
tologic evidence of viral infection [26]. CMV interstitial
pneumonitis (IP) previously had a mortality rate of approxi-
mately 85% [27]. Several interventions have dramatically
reduced the incidence of primary CMV infection, including
the use of CMV seronegative blood products in seronegative
patients, the use of antiviral agents for prophylaxis, and the
ﬁltering of blood products to remove CMV-infected white
blood cells [26,27]. The mortality rate of documented CMV
disease, however, remains approximately 50%, even with the
addition of ganciclovir and IVIG therapy [28]. In view of the
high mortality rate that accompanies CMV disease, therapy
usually is instituted when infection is documented but before
signs and symptoms of disease are present, ie, preemptively.
Studies using CMV IgG will be discussed separately due to
difﬁculty in standardizing products, problems with availabil-
ity, and increased cost compared to IVIG.
IVIG TO REDUCE INFECTIONS IN AUTOLOGOUS
TRANSPLANTATION AND NONTRANSPLANTATION
INTENSIVE CHEMOTHERAPY
Wolff and colleagues [29] designed a prospective, strati-
ﬁed, randomized study to examine whether IVIG prophy-
laxis could reduce the incidence of severe infections in
patients who would become neutropenic after autotrans-
plantation or nontransplantation intensive chemotherapy.
The frequencies of proven clinical infection, bacteremia,
and fungemia were 43%, 35%, and 6% for IVIG-treated
patients versus 44%, 34%, and 9% for the control group.
These data did not reach statistical signiﬁcance (P > .2), and
it was concluded that IVIG prophylaxis failed to reduce the
incidence of infections in autograft patients as well as in
patients receiving intensive chemotherapy (Table 1).
IVIG TO PREVENT CMV OR BACTERIAL INFECTION IN
ALLOGENEIC HSCT 
Emanuel and colleagues [30] reported in preliminary
fashion a prospective, randomized study that evaluated the
efficacy of IVIG (n = 46 patients) versus placebo (n = 46
patients) in reducing the incidence and severity of infectious
complications in allogeneic HSCT patients. Only manufac-
turer lots of IVIG that contained CMV IgG titers of
>1:6400 and a CMV neutralizing antibody titer of >1:500
were administered to patients. IVIG therapy had no impact
on overall or disease-free survival at 1 year or 3 years after
transplantation. The incidence or severity of bacterial infec-
tions, CMV infections, or CMV disease was not different
between treatment groups.
Graham-Pole and coworkers [31] showed a statistically
signiﬁcant beneﬁt in favor of IVIG therapy as CMV infec-
tion prophylaxis after HLA-identical sibling donor allo-
grafts. The ﬁrst 21 patients served as historic controls and
did not receive IVIG, and the next 29 patients were treated
with IVIG for infectious prophylaxis. IP, systemic viral, fun-
gal, or bacterial infections, or combinations thereof devel-
oped in 24.1% of the IVIG-treated group versus 66.7% ofTa
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the control group (P < .005). Mortality associated with these
infections also differed significantly (10.3% IVIG versus
57.1% controls P < .001). The authors concluded that IVIG
reduced the risk of all forms of serious infections and there-
fore improved survival in these patients.
Preliminary data were presented on 179 sibling-matched
allograft patients by Cordonnier and colleagues [32]. This
randomized, double-blind, placebo-controlled, multicenter
trial compared 3 different doses of IVIG for the end points
of infections, GVHD, veno-occlusive disease, survival, and
IP within the ﬁrst 6 months after allograft. The intent-to-
treat analysis showed no difference between any of the
groups with respect to the incidence, type of pathogens (bac-
terial, fungal, viral), or severity of infections, including
CMV infection and disease. Interestingly, veno-occlusive dis-
ease was absent in the placebo arm compared to an incidence
of 10.7%, 10.6%, and 17.5%, respectively, in the 50 mg/kg,
250 mg/kg, and 500 mg/kg IVIG groups (P =.025).
None of the above 4 trials showed a statistically signiﬁ-
cant beneﬁt to IVIG prophylaxis for the prevention of CMV
or bacterial infection per se. The trials reported by Wolff et
al. [29] and Graham-Pole et al. [31], however, did show a
signiﬁcant reduction in overall mortality compared to con-
trols. IVIG treatment was not used routinely in an allograft
study reported by Maltazou et al. [33]. They retrospectively
compared the incidence and mortality of CMV disease in
215 allogeneic marrow and peripheral blood stem cell recip-
ients who received 3 days versus 5 days per week IV ganci-
clovir 5 mg/kg doses (Table 1). CMV infection and disease
and CMV-related mortality were significantly lower with
use of 5 times weekly rather than thrice weekly ganciclovir,
although overall mortality did not differ. Patient characteris-
tics in the 2 study arms, however, differed considerably, and
the issue of whether IVIG can be omitted from CMV pro-
phylaxis cannot be determined by the results of this retro-
spective study.
IVIG PREEMPTIVE THERAPY FOR CMV INFECTION 
The initial, randomized controlled study that demon-
strated beneficial effects of IVIG for the modification of
CMV infection and prevention of CMV IP after sibling-
matched allogeneic HSCT was published by Winston and
colleagues in 1984 [34] and updated in 1987 (n = 75) [35]
(Table 2). Symptomatic CMV infection and IP (CMV or
idiopathic) occurred less frequently in the IVIG group,
although documented CMV-related IP and overall inci-
dence of CMV infection did not differ statistically.
The efﬁcacy of early combination therapy using ganci-
clovir and IVIG in CMV IP was examined in a single-arm
study by Lehn and collaborators in 21 patients who previously
had undergone HSCT for aplastic anemia, chronic myeloge-
nous leukemia, or acute leukemia [36]. Nine of 18 asympto-
matic patients died, but only 2 individuals expired due to
CMV IP. Two of the 3 patients with established CMV IP
became long-term survivors; the third patient died of causes
secondary to pulmonary aspergillosis. Although the study
sample size was small and no control group was included,
these data suggest that the initiation of combination therapy
when CMV is isolated, even in asymptomatic subjects, may
decrease the mortality of CMV IP.
In a double-blind, placebo-controlled trial, Goodrich and
coworkers [37] assessed the efﬁcacy and safety of ganciclovir
as prophylaxis for the development of CMV disease. A total
of only 19 subjects in both treatment groups were given IVIG
at various doses and schedules for acute GVHD prophylaxis
(n = 9) and for hypogammaglobulinemia (n = 10). Ganciclovir
therapy reduced the development of CMV disease, and over-
all survival was superior in the ganciclovir-treated group at
100 days and 180 days. Conclusions regarding the utility of
IVIG for preemptive CMV therapy are difﬁcult to assess, how-
ever, because only a small number of patients received IVIG.
Schmidt and associates [38] randomized sibling-
matched allograft recipients that had bronchoalveolar lavage
(BAL) positive for CMV to receive either IV ganciclovir or
observation. If CMV IP developed, patients were treated
with ganciclovir and IVIG [39]. Ganciclovir added to IVIG
therapy signiﬁcantly reduced the probability of CMV pneu-
monia (P = .0013) compared to that observed in uninfected
CMV seropositive patients. Within the ﬁrst 120 days after
allograft, the risk of CMV IP or death in the ganciclovir-
treated group was one-third that of the BAL culture–positive
patients randomized to observation alone (P = .015). Using
an intent-to-treat analysis, CMV IP or death occurred in
only 25% of those subjects randomized to ganciclovir versus
70% of the patients randomized to observation (relative risk
= 0.36, conﬁdence interval 0.16-0.8, P = .010). Although no
patient who completed the full course of induction and
maintenance ganciclovir therapy had CMV pneumonia, the
role of IVIG therapy cannot be assessed because all patients
in the study received this agent.
Mandanas and colleagues [40] administered ganciclovir
preemptive treatment to patients noted to have CMV recov-
ered from routine blood or BAL cultures. All patients
received routine IVIG therapy. Two of 12 patients with CMV
infection died of non-CMV causes, and the remaining
10 patients did not develop CMV sequelae. Although none of
the patients with CMV infection given ganciclovir treatment
had subsequent CMV-associated morbidity or mortality, the
utility of IVIG therapy in this setting cannot be assessed.
Wolff and colleagues [41] presented a preliminary
communication describing a randomized IVIG dose-
determination study in 618 markedly heterogeneous allo-
graft patients. CMV infection and disease rates and the
overall actuarial 1-year survival rate did not appear to differ
among the 3 IVIG doses.
Although the majority of these 6 studies in Table 2 were
randomized, the trials are heterogeneous with respect to
patient populations, IVIG dose, and use of ganciclovir. Few
of the trials were adequately controlled and most also used
ganciclovir therapy. IVIG monotherapy does not appear to
be efﬁcacious as preemptive therapy for CMV infection.
CMV IMMUNE GLOBULIN THERAPY
CMV IgG is produced from pooled plasma of more
than 2000 donors [26]. A criterion CMV-antibody titer of
1:1000 is used as the standard to which the CMV plasma
pool is subjected. The average CMV IgG antibody titer is at
least 1:7000 as measured by enzyme-linked immunosorbent
assay (ELISA). The antibody binding activity of this product
is 5 to 8 times higher than that of standard IVIG.
IVIG in Stem Cell Transplantation
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CMV IgG Therapy to Prevent CMV Infection 
The results of 6 studies designed to assess the use of
CMV IgG to prevent CMV infection are shown in Table 3.
Condie and O’Reilly [42] conducted a prospective, strati-
ﬁed, randomized trial to evaluate CMV hyperimmune glob-
ulin, CMV antibody–deficient plasma, and no immune
globulin therapy in 55 acute leukemia patients who had
undergone HSCT. The no-treatment group consisted of
matched subjects who had concurrently received transplants,
but did not receive plasma. The results showed a statistically
signiﬁcant beneﬁt in favor of CMV hyperimmune globulin
compared to CMV-deﬁcient plasma and to no therapy for
the incidence of CMV infection (0% versus 50%, P = .001,
and 0% versus 33%, P = .009, respectively). The incidence
of IP was statistically different for the CMV hyperimmune
globulin compared to no treatment (0% versus 30%, P =
.014). The CMV antibody–deﬁcient plasma was not statisti-
cally different from the hyperimmune globulin for the inci-
dence of IP. No patient treated with CMV IgG died com-
pared to 6 deaths among the 20 (30%) patients in the
control group (P = .014).
In a randomized multicenter trial, Kubanek and
coworkers [43] compared CMV IgG to standard IVIG for
the prevention of CMV infection in leukemia patients
undergoing HLA-matched sibling allografts. Only 4% of
the CMV IgG-treated patients versus 26% of the IVIG-
treated patients developed CMV IP (significant but the
P value was not provided).
Bowden et al. [44] investigated the effectiveness of
transfusing blood products seronegative for CMV and CMV
IgG for the primary prevention of CMV infection in CMV
seronegative patients in the ﬁrst 100 days following HSCT.
The randomization proceeded in a 2-step fashion; patients
were first randomized to receive either screened or
unscreened blood products and then to receive or not to
receive CMV IgG. Eighty-ﬁve patients were evaluated for
CMV infection. CMV IgG therapy was not associated with
protection against CMV infection or disease regardless of
the serologic status of the donor. The use of screened blood
products, however, did provide protection from primary
CMV infection and the subsequent development of disease
(P < .05 for both).
Einsele and colleagues [45] reported a beneﬁcial effect
of CMV IgG prophylaxis in a retrospective analysis of
41 patients at high risk for CMV infection following HSCT
(Table 3). Six patients developed CMV infection diagnosed
by culture, and 2 patients developed CMV gastroenteritis.
The overall incidence of CMV infection in this study was
very low considering that 61% of the recipients and 39% of
the donors were seropositive.
Bowden et al. [46] later published the results of a
prospective, randomized study designed to determine if
higher doses of CMV IgG reduced the incidence of CMV
infection or disease during the ﬁrst 100 days after allograft.
All allograft recipients were seronegative for CMV prior to
HSCT with a seropositive donor, were randomized to receive
CMV IgG or no therapy, and received unscreened blood
products. Although the probability of developing CMV infec-
tion was significantly less in those treated with CMV IgG
compared to controls (P = .04), the incidence of CMV disease
and overall mortality did not differ signiﬁcantly.Ta
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Ruutu et al. [47] reported a multicenter, prospective,
randomized trial designed to determine the effectiveness of
CMV IgG in the prevention of CMV infection and disease
in seronegative patients who had received either unscreened
blood products or an allograft from a seropositive donor
(Table 3). In this small series, CMV infection, CMV disease,
and overall survival did not differ between those given CMV
IgG therapy versus the no-treatment group.
Two of the 6 studies shown in Table 3 [42,46] demon-
strated a statistically signiﬁcant beneﬁt of CMV IgG com-
pared to no treatment as therapy to prevent CMV infection.
Small sample sizes and differences in the patient groups,
lack of benefit in the other studies, and no significant
improvement in reducing incidence of CMV disease and
overall mortality make it appear less likely that CMV IgG
provides a clinically signiﬁcant beneﬁt.
IVIG Treatment for CMV Disease 
Schmidt and coworkers [39] investigated the efficacy
of IVIG in combination with ganciclovir in 13 CMV-
seropositive HSCT patients who developed documented
CMV IP after allograft. Nine patients were alive after a
median 3-week follow-up; 4 patients died, 2 as a result of
CMV IP. Combination therapy eliminated detectable virus
in BAL specimens and resulted in resolution of clinical and
radiographic evidence of pneumonia. The authors con-
cluded that although IVIG is effective, the dose and fre-
quency necessary for successful therapy are unknown.
The European Bone Marrow Transplant Group [48]
retrospectively collected data via a questionnaire relating to
49 HSCT patients treated for CMV IP using the combina-
tion of IVIG (standard preparations or hyperimmune globu-
lin) and ganciclovir (Table 4). Twenty-eight patients
received high-dose (>200 mg/kg) IVIG therapy, 18 patients
received low-dose treatment, and in 3 patients, the dose was
unknown. Overall survival at 6 months after diagnosis of
CMV IP was 22%. Survival rates did not differ between
patients given CMV IgG versus standard IVIG therapy and
for those subjects treated with high-dose versus low-dose
IVIG therapy. In this retrospective report, lack of standard-
ization of IVIG therapy among the centers surveyed limits
conclusions regarding efﬁcacy.
These 2 trials (Table 4) provide no basis to formulate a
decision regarding the utility of IVIG as treatment for
CMV disease. Ganciclovir appears to be the primary ther-
apy; whether IVIG adds beneﬁt is unknown.
CMV IgG to Treat CMV Disease 
Blacklock and coworkers [49] reported a case series of
10 episodes of CMV pneumonitis in 9 patients after HSCT.
Six of 9 patients survived up to a median of 324 days after start-
ing therapy. The other 3 patients died of non-CMV causes.
The authors concluded that CMV IgG was effective therapy
for CMV disease, but a control group was not included.
A multicenter, randomized, controlled trial reported in
preliminary fashion by Jacobsen et al. [50] evaluated the
effectiveness of CMV IgG versus standard IVIG for the pre-
vention of lethal CMV IP post-HSCT. IP was the cause of
death in 22% of the 49 patients treated, with 14% due to
documented CMV IP. Although only 1 of 26 CMV IgG-
treated patients died of CMV IP versus 6 of 23 IVIG-
treated patients (P < .05), overall survival at day 110 after
allograft did not differ between groups (Table 4).
Aulitzky and associates [51] described 6 patients treated
with ganciclovir and CMV IgG for CMV disease (Table 4).
Five of 6 patients had undergone HSCT (4 allogeneic,
1 autologous), and 1 patient had systemic lupus erythemato-
sus. Upon study entry, 4 patients were intubated and
required mechanical ventilation. Only the 2 patients who did
not experience initial respiratory failure survived, whereas
the other 4 patients died of disseminated CMV disease. The
authors concluded that future trials should concentrate on
treating earlier forms of CMV disease because of the lack of
beneﬁt shown in their patients with advanced disease.
In an attempt to duplicate previous authors’ results,
Reed et al. [52] studied CMV IgG in 14 HSCT patients
who had biopsy-confirmed CMV pneumonia. The CMV
mortality rate was 79% in this group through day 130 after
allograft. Serum anti-CMV antibody concentration did not
differ between survivors and fatalities, and the authors rec-
ommended against CMV IgG monotherapy for CMV IP.
Disappointed with the results from the previous trials,
Reed and colleagues [53] then examined the efficacy of
CMV IgG in combination with ganciclovir for proven CMV
pneumonia in a 25-patient consecutive-entry trial (Table 4).
Twelve patients did not survive the initial episode of CMV
pneumonia. Of the 13 survivors, 4 relapsed; all were CMV
culture–positive on autopsy.
Emanuel et al. [54] reported on the efﬁcacy of combina-
tion ganciclovir and immunoglobulin therapy in the treat-
ment of 10 patients who had CMV pneumonia after HSCT
(Table 4). Eleven consecutive patients given CMV IgG or
IVIG as therapy for CMV pneumonia after allograft were
used as historic controls. The treatment group experienced
a 30% mortality rate, but no patient died from CMV disease
per se. None of the control (CMV IgG–treated) patients
survived (P = .001); CMV pneumonia was conﬁrmed in the
5 patients who had autopsies. This study showed that com-
bination therapy might be superior to monotherapy. Direct
comparisons are difficult, however, because 2 different
immunoglobulin products (standard and hyperimmune)
were used to treat the pneumonia. Similar disappointing
results were noted in which none of 6 consecutive patients
with biopsy-proven CMV pneumonia survived after HSCT
despite use of CMV IgG therapy [55].
Only 1 of these 7 trials shown in Table 4 demonstrated a
statistically signiﬁcant overall beneﬁt. Different researchers
have been unable to duplicate previous positive results, and
the utility of CMV IgG to treat CMV pneumonia appears to
be minimal.
IVIG THERAPY IN GVHD PROPHYLAXIS
IVIG has been hypothesized to have utility as an agent
that can modulate or reduce the severity of acute GVHD.
Postulated mechanisms include anti-idiotypic regulation and
inhibition of cytokines that mediate GVHD [56]. Sullivan
and associates [57] reported a stratiﬁed, randomized compar-
ison of weekly IVIG versus no IVIG therapy to assess IVIG
as an antimicrobial agent and as an immunomodulator of
acute GVHD (Table 5). In subjects younger than 20 years,
the incidence of acute GVHD did not differ signiﬁcantly. In
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older patients, the cumulative incidence of acute GVHD
grades II to IV was 51% in controls versus 34% in IVIG-
treated subjects (P = .0051). Additionally, the anti-GVHD
beneﬁt was most pronounced in patients who received HLA-
identical grafts (28% in IVIG-treated patients, 43% in con-
trol, P = .029). For subjects given HLA-nonidentical grafts,
the difference was not significant (49% in IVIG-treated
patients, 71% in controls, P = .078), but the trend was in the
same direction. Nonrelapse mortality did not differ between
treatment groups in patients younger than 20 years, but in
older patients given HLA-identical allografts, the cumulative
incidence of nonrelapse mortality favored IVIG treatment
(46% versus 30%, P = .023). In this trial, IVIG appeared to
provide effective acute GVHD prophylaxis in HLA-identical
HSCT recipients over age 20 years. Deﬁnite conclusions are
difﬁcult to formulate because of baseline differences between
groups, such as advanced stage of disease and the number of
patients in relapse for acute leukemia.
Cottler-Fox and coworkers [58] hypothesized that the
beneficial effects of IVIG were related to the serum IgG
concentration achieved and maintained and used a phase II
design to treat 22 patients with IVIG (Table 5). Grades II to
IV acute GVHD developed at a median of 13 days post-
HSCT in 10 patients whose mean serum IgG trough con-
centrations fell below 1200 mg/dL. On the other hand, no
patients experienced acute GVHD grades II to IV if their
serum IgG trough concentration consistently exceeded
1200 mg/dL (P < .01).
Klaesson and coworkers [59] retrospectively compared
45 sibling-matched allograft recipients given weekly IVIG
after transplantation versus 53 untreated historic controls.
Although grade I acute GVHD occurred earlier in the IVIG
group than in the control group (at day 25 versus day 35,
P < .05), there was no difference between the groups with
regard to the incidence of grade II to IV acute GVHD or
chronic GVHD.
In a study that suggests that IVIG may have long-term
adverse effects on immune reconstitution, Sullivan et al. [60]
prospectively compared 2 large groups of allograft patients
for the effect of IVIG on the incidence and severity of late
transplantation complications. Patients were stratiﬁed pre-
transplantation into 2 groups based on marrow source, disease
status, and patient CMV serology. Patients were random-
ized to receive either monthly IVIG from 90 days posttrans-
plantation until 1 year after transplantation, or no IVIG
after day 90. The cumulative incidence of chronic GVHD
did not differ at 1 year. Importantly, extending IVIG treat-
ment beyond 3 months was associated with delayed recovery
of humoral immunity, as shown by serum IgG1 and IgA lev-
els that were significantly lower for IVIG-treated patients
than for control patients at 2 years after transplantation (P =
.035 for IgG1, P = .037 for IgA). In the second year post-
transplantation, the rate of infections was increased signiﬁ-
cantly for IVIG recipients compared to untreated control
patients, but overall and nonrelapse mortality at 100 days
did not differ.
Winston and associates [61] conducted a randomized,
double-blind, multicenter trial in 618 patients assigned to
receive IVIG at 1 of 3 dose levels (Table 5). The overall inci-
dence of acute GVHD was similar among all of the IVIG
dose groups (39% for 100 mg/kg, 42% for 250 mg/kg, and
35% for 500 mg/kg, P = .344). No statistically significant
differences were noted among the 3 IVIG dose groups for
incidence of acute GVHD, and infection and overall 1-year
survival rates were approximately 50% for each subgroup.
Abdel-Mageed and associates [62] reported a 332-patient,
randomized, unblinded, multicenter study comparing
weekly IVIG therapy at 2 different doses for influencing
incidence of systemic infection and acute GVHD (Table 5).
The IVIG dose did not influence event-free survival or
infectious risk, and nearly half of all patients developed
grade II to IV acute GVHD. Use of the 500 mg/kg dose was
associated with a significantly lower incidence of acute
GVHD compared to the 250 mg/kg group (44% versus 58%,
P = .03), although the incidence for speciﬁc grades of GVHD
was not stated. This study is the only published trial to date
that demonstrates superiority of one IVIG dose (500 mg/kg)
versus another (250 mg/kg) for GVHD prophylaxis.
Feinstein et al. [63] reported a randomized, open-label,
241-patient comparison of early intensive IVIG prophylaxis
versus no IVIG prophylaxis in an attempt to reduce the inci-
dence of acute GVHD and transplantation-related mortality
in adults undergoing allografts from related donors (Table 5).
Grades II to IV acute GVHD rates were approximately 20%
lower in the IVIG-treated patients who achieved peak
serum IgG concentrations of at least 3000 mg/dL, but this
difference was not statistically signiﬁcant. The study illus-
trated that use of IVIG in this fashion did not affect trans-
plantation-related mortality, overall survival at 6 years, or
the incidence of overall grade or severity of acute GVHD.
Sullivan and coworkers [64] recently reported prelimi-
nary results of a 497-patient placebo-controlled, double-
blind, multi-institutional trial designed to examine the role
of IVIG prophylaxis in reducing transplantation-related
mortality in HSCT patients receiving unrelated donor
grafts (Table 5). The cumulative incidence of transplanta-
tion-related mortality and relapse at 6 months for the con-
trol and IVIG groups was not statistically different (29%
versus 34%, P = .30, and 10% versus 7%, P = .41, respec-
tively). Incidence of acute GVHD (70% versus 71%) and
chronic GVHD (65% versus 62%) did not differ [64].
Most of the 8 studies shown in Table 5 failed to show a
statistically significant benefit of IVIG for acute GVHD
prophylaxis. One trial demonstrated superiority of a higher
IVIG dosage regimen, and the studies that monitored and
adjusted serum IgG concentrations [58,63] suggested a
potential beneﬁcial effect on reducing acute GVHD.
MONITORING PROGRAM FOR APPROPRIATE IVIG USAGE 
In response to product acquisition problems and costs,
University Hospitals of Cleveland, Cleveland, Ohio, a tertiary-
care medical center, implemented a usage and monitoring
plan for IVIG via an Ad Hoc Subcommittee of the Pharmacy
& Therapeutics Committee. This group, comprising indi-
viduals from all disciplines who possessed appropriate exper-
tise, began by reviewing published medical literature and
guidelines for IVIG use from several different organizations
[8,10,15,65]. A rank usage list of disease states was compiled
to ensure the availability of drugs for acute and life-threatening
disease states ﬁrst (see Figure for the top 3 disease states). A
point of a critical supply was deﬁned (<500 g hospital-wide)
D. R. Sokos et al.
126
Ta
bl
e 
5.
 S
tu
di
es
 D
es
ig
ne
d 
to
 A
sse
ss 
R
ol
e 
of
 IV
IG
 in
 P
re
ve
nt
in
g 
G
V
H
D
 in
 H
SC
T
*
N
o
. o
f
T
ra
ns
pl
an
ta
ti
o
n-
R
el
at
ed
C
it
at
io
n
P
at
ie
nt
s
T
ra
ns
pl
an
t 
T
yp
e
T
ri
al
 D
es
ig
n
IV
IG
 D
o
se
A
cu
te
 G
V
H
D
O
ve
ra
ll 
M
o
rt
al
it
y
M
o
rt
al
it
y
57
32
5
22
0 
H
L
A
-i
de
nt
ic
al
;
R
an
do
m
iz
ed
, 
50
0 
m
g/
kg
 p
er
 w
k 
×
15
 w
k,
A
ge
 <
20
 y
, n
o
 d
iff
er
en
ce
;
N
o
 d
iff
er
en
ce
 a
t 
2 
y
N
o
nr
el
ap
se
: 4
6%
 c
o
nt
ro
l
10
5 
no
ni
de
nt
ic
al
st
ra
ti
fi
ed
th
en
 q
m
o
 t
o
 1
 y
 v
s 
no
ag
e 
>2
0,
 5
1%
 c
o
nt
ro
l v
s
vs
 3
0%
 I
V
IG
 (
P
= 
.0
23
) 
in
tr
ea
tm
en
t
34
%
 I
V
IG
 (
P
= 
.0
05
1)
H
L
A
-i
de
nt
ic
al
 ≥
20
 y
 
58
22
18
 H
L
A
-i
de
nt
ic
al
;
P
ha
se
 I
I
50
0 
m
g/
kg
 p
er
 w
k 
 ×
6 
w
k,
G
ra
de
 I
I-
IV
 in
 1
0 
pa
ti
en
ts
; 
—
—
 
6 
no
ni
de
nt
ic
al
th
en
 e
ve
ry
 o
th
er
 w
k 
 
no
ne
 if
 s
er
um
 I
gG
 c
o
nc
 
×
5 
do
se
s
>1
20
0 
m
g/
dL
59
98
H
L
A
-i
de
nt
ic
al
 s
ib
lin
g
R
et
ro
sp
ec
ti
ve
50
0 
m
g/
kg
 p
er
 w
k 
un
ti
l 9
0 
d
N
o
 d
iff
er
en
ce
 fo
r 
gr
ad
es
N
o
 d
iff
er
en
ce
V
O
D
 2
5%
 I
V
IG
 v
s 
0%
 
re
vi
ew
vs
 n
o
 t
re
at
m
en
t
II
-I
V
 o
r 
ch
ro
ni
c 
G
V
H
D
co
nt
ro
l (
P
= 
.0
2)
  
60
17
4
A
llo
ge
ne
ic
R
an
do
m
iz
ed
50
0 
m
g/
kg
 p
er
 m
o
 a
t 
90
 d
N
o
 d
iff
er
en
ce
; f
o
r 
ch
ro
ni
c
N
o
 d
iff
er
en
ce
N
o
 d
iff
er
en
ce
 in
 n
o
nr
el
ap
se
un
ti
l 1
 y
 v
s 
no
 c
o
nt
in
ue
d
G
V
H
D
, 2
3%
 e
ac
h 
gr
o
up
m
o
rt
al
it
y 
af
te
r 
10
0 
d
tr
ea
tm
en
t
61
61
8
H
L
A
-i
de
nt
ic
al
 r
el
at
ed
R
an
do
m
iz
ed
, 
10
0 
vs
 2
50
 v
s 
50
0 
m
g/
kg
10
0 
m
g/
kg
 3
9%
 v
s 
25
0 
m
g/
kg
50
%
 e
ac
h 
gr
o
up
 a
t 
1 
y
—
an
d 
un
re
la
te
d,
 
do
ub
le
-b
lin
d,
 
w
k 
×
90
 d
 t
he
n 
qm
o
42
%
 v
s 
50
0 
m
g/
kg
 3
5%
m
is
m
at
ch
ed
, T
-c
el
l 
m
ul
ti
ce
nt
er
qm
o
 fo
r 
1 
y
(P
= 
.3
44
)
re
pl
et
e 
an
d 
T
-c
el
l 
de
pl
et
ed
62
33
2
H
L
A
-i
de
nt
ic
al
 a
nd
 
R
an
do
m
iz
ed
, 
25
0 
vs
 5
00
 m
g/
kg
 p
er
 w
k
58
%
 2
50
 m
g/
kg
 v
s 
44
%
N
o
 d
iff
er
en
ce
 in
 
—
 
co
m
pa
ti
bl
e,
 a
ll
m
ul
ti
ce
nt
er
fo
r 
18
 w
k
50
0 
m
g/
kg
 (
P
= 
.0
3)
, a
ll 
ev
en
t-
fr
ee
 s
ur
vi
va
l
re
la
te
d
gr
ad
es
 G
V
H
D
63
24
1
76
%
 H
L
A
-i
de
nt
ic
al
 
R
an
do
m
iz
ed
50
0 
m
g/
kg
 d
 –
6 
to
 d
 –
1,
 t
he
n
N
o
 d
iff
er
en
ce
 (
P
> 
.2
0)
N
o
 d
iff
er
en
ce
 a
t 
6 
y
N
o
 d
iff
er
en
ce
 (
P
= 
.9
2)
re
la
te
d
10
0 
m
g/
kg
 q
 3
 d
 u
nt
il
(P
= 
.1
1)
 
90
 d
 v
s 
no
 t
re
at
m
en
t
64
49
7
H
L
A
-i
de
nt
ic
al
 r
el
at
ed
 
R
an
do
m
iz
ed
,
50
0 
m
g/
kg
 p
er
 w
k 
un
ti
l 9
0 
d
N
o
 d
iff
er
en
ce
 (
70
%
 v
s 
71
%
)
—
A
t 
18
0 
d,
 2
9%
 c
o
nt
ro
l v
s
an
d 
un
re
la
te
d,
 
do
ub
le
-b
lin
d,
 
vs
 p
la
ce
bo
 (
gi
ve
n 
IV
IG
 
34
%
 I
V
IG
, (
P
= 
.3
0)
;
m
is
m
at
ch
ed
, T
-c
el
l 
pl
ac
eb
o
 
50
 m
g/
kg
 p
er
 w
k 
if 
se
ru
m
   
re
la
ps
e 
10
%
 c
o
nt
ro
l v
s
re
pl
et
e
co
nt
ro
lle
d
Ig
G
 <
40
0 
m
g/
dL
)
7%
 I
V
IG
 (
P
= 
.4
1)
T
o
ta
l
23
07
*c
on
c 
in
di
ca
te
s 
co
nc
en
tr
at
io
n;
 V
O
D
, h
ep
at
ic
 v
en
o-
oc
cl
us
iv
e 
di
se
as
e.
IVIG in Stem Cell Transplantation
127B B & M T
at which an allocation process would be implemented under
the direction of the hospital pharmacy. At such time, patients
receiving maintenance-dose IVIG would continue to receive
the drug but at a 50% dose reduction until supply was
increased. HSCT patients who developed CMV infection or
disease were given high priority, immediately behind patients
with Kawasaki’s disease or primary immunodeﬁciencies and
infection, and were to receive full doses (250-500 mg/kg) at
regularly scheduled intervals (2 or 3 times per week). Main-
tenance doses for prophylaxis in allograft recipients were
ranked lower and occasionally were decreased by 50%.
Other conservation guidelines included rounding doses
down to the nearest whole vial size and dosing all patients
based on ideal body weight.
Data on all IVIG doses ordered were collected during a
3-month period, including patient age, weight, indication
for use, renal function, alternative therapies failed/con-
traindicated, prescribing service, and brand of IVIG dis-
pensed. Based on these data, the Ad Hoc Subcommittee, in
conjunction with the Division of Hematology-Oncology
and the Department of Neurology, further deﬁned each dis-
ease indication and dosage recommendation. The Pharmacy
Department continues to monitor usage. Based on such
data, a new policy was implemented in which allogeneic
HSCT patients were given IVIG 500 mg/kg when serum
IgG fell below 400 mg/dL (frank hypogammaglobulinemia).
SUMMARY AND FUTURE CONSIDERATIONS
IVIG and CMV IgG infusions are associated with an
extremely low incidence of serious adverse events. The efﬁ-
cacy data for use of these agents to prevent disease from
CMV, however, are very difficult to interpret. Ganciclovir
therapy clearly represents the cornerstone of therapy.
Investigations that included ganciclovir in the therapeutic
approach improved patient outcome compared to those
Monitoring program for evidence-based IVIG usage. ITP indicates idiopathic thrombocytopenic purpura; GB, Guillain-Barré; MG, myasthenia
gravis; MS, multiple sclerosis; MMN, multifocal motor neuropathy; resp, respiratory.
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strategies in which ganciclovir was not part of the anti-
CMV regimen. The time of onset for initiating therapy for
CMV infection and disease also appears to be important, yet
many trials enrolled patients before PCR technology for
CMV detection was widely available and acceptable. Thus,
there was suboptimal sensitivity of CMV detection. Unan-
swered questions include: Will earlier treatment with ganci-
clovir and IVIG or CMV IgG, as indicated by PCR testing,
improve outcomes? And what is the most appropriate dura-
tion of therapy for CMV treatment?
Data from studies using IVIG therapy to prevent the
onset of GVHD are more extensive. More than 2300
patients were enrolled in the trials reviewed herein. Only 1
randomized clinical trial, however, demonstrated a benefi-
cial effect of IVIG for acute GVHD prophylaxis. Further-
more, prolonged use of IVIG was shown to delay recovery
of humoral immunity after HSCT. IVIG therapy does not
appear to be efﬁcacious in decreasing the incidence or sever-
ity of chronic GVHD. A potential area for investigation is
the utility of targeted trough levels for dosing IVIG instead
of a set dosing interval.
The studies that address the use of IVIG in the allogeneic
HSCT patient provide limited data on the basis of which to
advise practitioners. Only a few trials have been randomized
and blinded, and data have been obtained mostly in patients
markedly heterogeneous for age and disease states, prepara-
tive regimens, GVHD prophylaxis approaches, and allogeneic
donor sources. The total number of patients studied is rela-
tively small given this degree of heterogeneity; hence, reports
are unlikely to show signiﬁcant beneﬁt in any given patient
subset. Finally, it is unclear whether any one of the many
available products is superior to another [66]. As a result, con-
clusions regarding use of this expensive product are limited.
Many questions remain unanswered regarding appropri-
ate use of IVIG therapy. Umbilical cord blood transplanta-
tion is a new modality in which the role of IVIG or CMV
IgG therapy has yet to be defined [67]. At this point, we
would at least conclude that IVIG should be used at regular
replacement doses (300-600 mg/kg) in all patients who are
frankly hypogammaglobulinemic (serum IgG < 400 mg/dL)
and that ganciclovir should be included in the treatment of
all patients who have documented CMV disease. Elucidat-
ing the mechanism of action, including determining effects
on lymphocyte and monocyte function in the immune
cytopenias and interaction with cytokines, may provide
insight regarding the appropriate use of this expensive ther-
apy [19]. Mechanisms of action and efficacy of different
products may not be the same in prevention, treatment of
disease, and modulating GVHD. The appropriate patient
candidate, IVIG dose, frequency of administration, and
length of therapy are all unknowns. In the interim, we have
adapted a monitoring policy to ensure a more homogeneous
approach to use of this product.
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